1 Treatment and Cost -outcomes of a simplified antiretroviral treatment strategy for 2 hepatitis C among HCV and HIV co-infected patients in Ukraine

3

4

5 Sergie Antoniuk¹, Charles Chasela C^{2,3±}, Morgan J Freiman⁴, Yulia Stopolianska¹, Tetiana
6 Barnard⁵, Gandhi MM⁶, Maria Liulchuk⁸, Zhanna Tsenilova⁹, Tretiakov V¹⁰, Jeri Dible⁵,
7 Constance Wose Kinge^{2,11}, Minior T⁵, Sofiane Mohamed^{12, 12}, Fadzai Marange², Clint
8 Cavanaugh⁵, Charles van der Horst¹³, Svitlana Antonyak⁷, Thembisile Xulu², Kara W Chew⁶,
9 Ian Sanne^{2,14,15}, and Sydney Rosen^{4,14}, for EQUIP Health*.

10

11 Affiliation

12 ¹Right to Care, Kiev, Ukraine, ²Right to Care, Centurion, Pretoria, South Africa, ³Department of Epidemiology and Biostatistics,
13 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ⁴Boston
14 University, Boston, MA, USA, U.S. ⁵United States Agency for International Development; ⁶David Geffen School of Medicine at
15 UCLA, Los Angeles, CA, USA, ⁷Public Health Centre of Ministry of Healthcare of Ukraine, ⁸Gromashevsky Research Institute
16 of Epidemiology and Infection Diseases, Medical Academy of Sciences of Ukraine; ⁹Alliance for Public Health, Kyiv,
17 ¹⁰Ukraine; 100%Life, Kyiv, Ukraine, ¹¹Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, School of
18 Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ¹²Advanced
19 biological laboratories (abl) SA.17, rue des jardiniers, Luxembourg 1835, ¹³University of North Carolina, Chapel Hill ¹⁴Health
20 Economics and Epidemiology Research Office, ¹⁵Department of Internal Medicine, School of Clinical Medicine, Faculty of
21 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,

22

23 * EQUIP is a consortium of local African Non-Governmental Organisation that were funded by USAID to assist
24 countries through innovations to meet the UNAIDS 90, 90 90 targets.

25

26 [±]**Corresponding author Address:** Implementation Science and Research Unit, Right to Care,
27 1006 Lenchen Avenue North, Centurion. Pretoria. Gauteng. South Africa.

28 **Telephone:** +27765240898, **Email Address:** charles.chasela@wits.ac.za

29

30 **Key words:** HCV, HIV, Sustained Virologic Response, PWID, Ribavirin, LDV/SOF,

31 Electronic Word Count

32 Number of Figures: 2 and Tables 6

33

34

35 **Abstract**

36 **Background:** We conducted a demonstration project of an integrated HIV and viral hepatitis
37 testing and treatment strategy using generic ledipasvir/sofosbuvir (LDV/SOF).

38 **Methods:** Eligible HCV viraemic adults from two clinics in Kyiv were treated with LDV/SOF
39 +/- weight-based ribavirin for 12 weeks. Clinical assessments were performed at screening and
40 week 24 and as needed; treatment was dispensed every 4 weeks. The primary outcome was
41 sustained virologic response (SVR)12 weeks after treatment. Program costs in 2018 USD were
42 estimated per patient treated using observed resource utilization, local unit, and antiretroviral
43 therapy (ART) costs over the 24-week period.

44 **Results:** 868 participants initiated on treatment, 87% (755) were PWID and 55.5% (482) were
45 HIV co-infected. The common genotypes were 1 (74.1%) and 3 (22%) and SVR was achieved
46 in 831/868 (95.7%) by intention-to-treat analysis. The average cost per patient treated was \$680,
47 assuming generic LDV/SOF and ribavirin pricing and standard quantitative HCV viral load
48 testing. Medications comprised 38% of the average cost/patient, laboratory tests 26%, events
49 (clinic visits, counselling) 10%, and indirect costs 26%. ART accounted for 60% of all drug
50 costs, with HCV medications just 40%.

51 **Conclusion:** Generic LDV/SOF +/- ribavirin provided produced exceptionally good outcomes
52 including amongst patients with genotype 3 HCV and PWID at an average cost of <\$700/patient
53 year, including ART for those with HIV. Under the assumptions of generic drug pricing but
54 higher laboratory costs, an average cost of \$750/patient is likely a reasonable estimate for this
55 intervention in Ukraine, excluding costs for scaling or maintaining the treatment program.

56

57 **Electronic Word Count: 250**

58 Introduction

59 Globally, an estimated 71 million people are living with chronic hepatitis C virus (HCV)
60 infection and are at risk for significant morbidity, including liver cirrhosis, liver failure,
61 hepatocellular carcinoma and death¹⁻³. Even in low-HCV prevalence settings, HCV infection
62 remains common among people who inject drugs (PWID) and HIV-infected men who have sex
63 with men (MSM)^{1,4}. Despite the development of highly effective direct-acting antiviral (DAA)
64 treatment, which can cure HCV infection with 8-12 weeks of therapy, HCV remains a leading
65 cause of mortality worldwide, causing more than 350,000 deaths each year^{5,65}. Of these, 85,000
66 are in Eastern Europe⁷, including Ukraine. The WHO's Global Health Sector Strategy sets goals
67 of a 90% reduction in new HCV infections and a 65% reduction in HCV-related mortality by
68 2030^{8,9}. Progress in HCV treatment scale-up has been encouraging, with more than 3 million
69 treated globally with direct-acting antivirals since 2015. Testing and diagnosis rates are still less
70 than 10% in LMICs, however¹⁰.

71

72 In Ukraine, roughly 3-5% of the population—as many as 2 million people—are estimated to
73 be HCV-infected¹¹. Those most at risk are PWID, people living with HIV (PLHIV), sex workers
74 (SW), MSM, prisoners, members of the military, populations in conflict zones, and sexual
75 partners of PLHIV. A lack of adequate facilities and free-to-client services, combined with fear
76 of prosecution for drug use and stigma suffered by key populations, particularly PWID and
77 MSM,, means that most individuals who present for treatment for HCV and HIV are already well
78 advanced in their illness¹².

79

80 Low cost, scalable, integrated HIV and HCV testing and treatment strategies offer a chance
81 to achieve WHO targets for HIV and HCV elimination in dual epidemic regions. We describe
82 the treatment outcomes and estimated costs for an integrated HIV and HCV treatment program

that offered HCV treatment with 12 weeks of sofosbuvir/ledipasvir (LDV/SOF) with or without weight-based ribavirin (WBR) in Ukraine.

Patients and Methods

Study sites and population

Enrolment into the HCV/HIV demonstration project was conducted in 2018 at two clinical facilities in Kyiv, Ukraine: the Clinic of the Gromashevsky Institute of Epidemiology and Infectious Diseases and Treatment, and Kyiv City Clinical Hospital #5. Patients were recruited to the study from HCV treatment waiting lists available at the sites, were referred by partner organizations, or had a positive HCV antibody or RNA test at one of the sites during the enrolment period. Target populations for study enrolment were PWID, MSM, SW, and sexual partners of HCV-infected individuals, though these characteristics were not required for enrolment.

Study eligibility

Eligible participants included in the treatment study were HCV viraemic, HCV treatment naïve or experienced (prior pegylated interferon [PegIFN] and ribavirin [RBV] only), and 18 years or older, with HCV genotype 1, 2, 3, 4, 5 or 6 and with or without HIV-1 co-infection. Patients with compensated cirrhosis (Child-Pugh Class A) and hepatitis B virus (HBV) infection were eligible; those with decompensated cirrhosis (Child-Pugh Class B or C) or prior treatment with HCV DAAs were not and referred to other treatment centres for care. All participants provided written informed consent.

105 **Intervention**

106 The intervention combined HCV and HIV testing, HCV treatment, simplified HCV
107 treatment monitoring, and HIV treatment initiation for those with HIV co-infection not yet on
108 antiretroviral therapy. HCV treatment was with fixed-dose combination ledipasvir/sofosbuvir/
109 (LDV/SOF) 400 mg/90 mg +/- weight-based ribavirin (1000 mg for patients <75 kg and 1200
110 mg for those ≥ 75 kg administered orally in two divided doses) for 12 weeks and provided by the
111 project. Ribavirin was included in the regimen for treatment experienced cirrhotic genotype 1
112 and 4 participants and all participants with genotype 3 HCV. HIV treatment was per national
113 guidelines, within the National HIV treatment program¹³. Participants with HBV co-infection
114 and hepatitis B surface antigen positivity were concurrently treated with tenofovir. Participants
115 were followed for 24 weeks (through 12 weeks after treatment completion), including
116 assessments of HCV and HIV treatment outcomes and safety. Intervention steps are illustrated in
117 Figure 1. A four-week supply of study medications was dispensed at weeks 0, 4, and 8 and
118 psychosocial and peer support were provided at entry, 4, 8, 12 and 24 weeks. Participants not
119 already on medication-assisted treatment (MAT) were referred for harm reduction, including
120 MAT programs.

121 **Clinical and laboratory evaluations**

122 *Clinical evaluations and drug dispensing*

123 A complete clinical assessment including medical history, physical exam, and review of
124 concomitant medications was performed at screening. Subsequently, clinical assessments were
125 driven by reported symptoms and required only at entry and week 24. Liver disease stage
126 (presence or absence of cirrhosis) was defined by any of the following and by the study
127 physician's judgement: cirrhosis on liver ultrasound; liver histology (liver biopsy); AST-to-
128 platelet ratio index (APRI) >1.0 and FIB-4 >3.25; or liver stiffness by transient elastography

(Fibroscan) ≥ 12.5 kPa. Child-Pugh scores were calculated for all cirrhotic patients, with compensated cirrhosis defined as Child-Pugh score ≤ 6 (Class A).

Laboratory evaluations

Pre-treatment laboratory tests included HCV antibody if not already available, HCV RNA for HCV antibody positive participants, haemoglobin, platelets, aspartate, aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, creatinine, blood urea nitrogen, pregnancy testing, prothrombin time/International Normalized Ratio (INR), HBV serologies (hepatitis B core Ab (HbcAb), hepatitis B surface antigen (HbsAg), hepatitis B surface antibody (HBsAb)), and CD4+ T cell count for HIV-infected participants. Laboratory results were also obtained from the medical record if available within the specified window.

The protocol called for all participants who initiated HCV treatment and remained in care to have the following laboratory tests at week 24: HCV RNA, haemoglobin, platelets, AST, ALT, bilirubin, albumin, creatinine, blood urea nitrogen, prothrombin time/INR, and HIV RNA. Participants receiving ribavirin had haemoglobin monitoring at weeks 2, 4, and 8 and pregnancy testing (for females of childbearing potential) at weeks 4, 8, 12, and 24. Participants with eGFR <60 at screening and also receiving tenofovir disoproxil fumarate (TDF) had creatinine monitoring at weeks 4 and 12. Participants with isolated hepatitis B core Ab (HBcAb+/HBsAg-/HBsAb-) additionally had hepatic function tests (AST, ALT, total bilirubin) measured at weeks 4, 8, and 12 to monitor for HBV reactivation. Quantitative HCV viral load (real time RT-PCR reagent kit D-0794, Vector Best) and HCV genotyping (hybridization-fluorescence, AmpliSense HCV-genotype-FL reagent kit, Central Epidemiology Research Institute, Russian Federation) were performed at the Synevo central laboratory in Kyiv for all participants.

152 **Outcomes**

153 The two primary outcomes of the analysis were virologic status at week 24 and cost per
154 patient, stratified by outcome. We assigned each patient one of four virologic status outcomes at
155 24 weeks after treatment initiation: 1) treatment success, defined as sustained virologic response
156 (SVR) at 12 weeks after the end of treatment (week 24); 2) treatment failure (HCV viremia
157 greater than the lower limit of detection 12 weeks after therapy completion); 3) loss to follow up
158 (did not return to clinic for 24-week evaluation); or 4) death (died within the 24-week study
159 period). Other outcomes included safety (adverse events) during the treatment period.

160 **Data analysis**

161 *Outcomes*

162 Baseline sociodemographic, clinical, and laboratory characteristics of the participants were
163 calculated using proportions or means (standard deviations) or medians (interquartile ranges) for
164 continuous data. The proportion with SVR was calculated for each clinical site and overall, by
165 intention to treat (ITT). Differences between those successfully treated SVR achieved compared
166 to those who failed treatment were assessed by t test or chi-square test as appropriate, and by
167 multivariable logistic regression. A p-level of less than 0.2 in the bivariate analysis was used to
168 select variables for multivariable analysis. A final model was determined using stepwise
169 backward elimination method and only p-level of less than 0.05 were considered for the final
170 model. Multi collinearity test and Hosmer-Lemeshow test (HL test) for logistic regression were
171 undertaken on the final model. Data were analysed using STATA version 15 SE (StataCorp
172 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC).

173 *Costs*

174 Costs were estimated from the provider perspective from initial screening date until
175 assessment of cure 12 weeks after HCV treatment completion (24 weeks total) using standard

176 micro-costing methods described previously^{14,15}. Resource costs are reported in four categories:
 177 1) indirect costs (support staff/personnel, building costs, equipment, and office supplies,
 178 including education and outreach costs); events (physician visits, counselling visits, and
 179 Fibroscans; laboratory tests (HCV viral load modeled using the centralized laboratory pricing at
 180 the Synevo laboratory, HCV genotyping, HIV and HBV testing, pregnancy testing if applicable,
 181 PT/INR, blood counts, chemistries, and imaging); and medications (HCV, HBV, and HIV).
 182 Costs incurred solely for research purposes (e.g. obtaining informed consent, data entry, etc.)
 183 were not included.

184

185 We determined variable patient resource utilization from a de-identified dataset compiled
 186 from study participant case reporting forms and estimated resource utilization from average
 187 clinic site capacity and total annual visits. We then multiplied the quantity of each resource used
 188 by each patient by the associated unit cost to determine a total cost per patient. We evaluated the
 189 average resource utilization per patient by cost category and the four HCV treatment outcomes
 190 defined for the cost analysis and estimated 95% confidence intervals by outcome category. Cost
 191 estimates utilized data from a subset of all patients enrolled in the study; the subset included
 192 sequentially enrolled patients during the first six months of the enrollment period.

193

194 Study data were managed with HepatiC® (ABL SA, Luxembourg). The patient resource
 195 utilization matrix for this study was generated using SAS software, Version 9.3 (SAS Institute
 196 Inc., Cary, NC, USA). Estimates per patient treated and per successful outcome were made using
 197 the HE²RO Healthcare Costs and Outcome Model ([http://www.heroza.org/researchtools/the-](http://www.heroza.org/researchtools/the-healthcare-cost-and-outcomes-model-hcom)
 198 [healthcare-cost-and-outcomes-model-hcom](http://www.heroza.org/researchtools/the-healthcare-cost-and-outcomes-model-hcom)) (HE²RO, Johannesburg, South Africa). Economic
 199 models were generated with Excel 2011.

200 **Ethical considerations**

201 The study was reviewed by the Ukrainian Institute on Public Health Policy IRB #1,
202 Institutional Review Board (00007612) and the University of the Witwatersrand Human
203 Research Ethics Committee (M17078). The Boston University Institutional Review Board
204 approved analysis of a de-identified analytic dataset (H-37820). All participants provided written
205 informed consent. The study is registered at ClinicalTrials.gov (NCT04038320).

206 **Results**

207 **Enrolment and patient characteristics**

208 We consented 943 anti-HCV positive participants and enrolled those eligible at the
209 Gromashevsky and Kyiv Hospital between 26 March and 02 November 2018. As shown in
210 Figure 2, 43 participants were excluded after consent, leaving 900 eligible for treatment. Of
211 these, 868 were initiated on treatment, and 860 were assessed for SVR at 12 weeks after
212 treatment. Of those initiated on treatment, 44.1% (383) were HCV mono-infected, 55.5% (482)
213 HCV/HIV infected, 0.3% (3) HCV/HBV infected. Most HCV mono-infected participants were
214 recruited at the Kyiv City Hospital, while most HCV/HIV co-infected participants were from
215 Gromashevsky. Out of the 868 who started treatment, 87% (755) were PWID, of whom 60.7%
216 (434) were on MAT; most PWID were seen at Gromashevsky. The majority of participants,
217 91.8% (797), were not cirrhotic (Table 1). The mean APRI Score was 0.5 (0.3-0.8).

218

219 The most common HCV genotypes were 1 (74.1%) and 3 (22.0%) (Table 1). The median
220 (interquartile range, IQR) HCV RNA was 6.1 (5.7-7.1) log₁₀IU/ml. Among those HIV infected
221 (n=482), the median CD4 count was 507 cells/mm³ (351-704), and majority had HIV viral
222 suppression (<200 copies per millilitre of blood) at entry. 20 had detectable viral load with a
223 median (interquartile range) of 72 (52.5-267) copies per millilitre of blood; and 5 were

224 unsuppressed (>200 copies per millilitre of blood). At 24 weeks, 12 weeks after the completion
225 of HCV treatment, only two had unsuppressed viral loads.

226

227 **Treatment outcomes**

228 Treatment outcomes by site are reported in Table 2. Of the 868 patients who initiated HCV
229 treatment, 214 were treated with ribavirin. There were 80 adverse events reported, with 29, 20,
230 19 and 12 events at weeks 4, 8, 12 and 24 weeks, respectively. Of the 80 adverse events, 76.5%
231 were mild and the rest moderate; 92.6% were either anaemia or hyperbilirubinemia, 3 were due
232 to skin rash and itching, and 1 had lobar pneumonia. The majority 86.3% (69) were deemed study
233 drug related; 89.9% (62/69) Ribavirin related events were managed by reduction of the dose and
234 all SOF/LDV events were self-resolved.

235

236

237

238

239

240 Table 1: Patient characteristics by treatment site

Characteristic	Gromashevsky n=434	Kyiv City Clinic n=434	Total N=868
Age (years) (Median, interquartile range)	39 (35-43.7)	39 (35-45.8)	39(35-44.7)
Sex (%): Female	142 (32.7)	153 (35.3)	295 (34.0)
Education beyond primary (%)	285 (65.7)	288 (65.4)	573 (66.0)
Risk groups (%)			
Non PWID	77 (17.7)	35 (8.3)	113 (13)
PWID	357 (82.3)	398 (91.7)	755 (87)
PWID on MAT	243 (98.4)	191 (91.8)	434 (95.4)
Marital status: never married (%)	348 (80.2)	351 (80.9)	699 (80.5)
Median BMI (Kg/m ²) (IQR)	23.8 (21.5-26.3)	24.0 (21.9-26.6)	23.9 (21.6-26.5)
Cirrhosis %			
Compensated cirrhosis	41 (9.5)	30 (6.9)	71 (8.2)
No cirrhosis	393 (90.6)	404 (93.1)	797 (91.8)
Infection status (%)			
HCV mono-infected	133 (30.7)	250 (57.6)	383 (44.1)
HCV/HIV	301 (99)	181 (98.4)	482 (55.2)
HCV/HBV	0 (0.0)	3 (1.6)	3 (0.3)
Genotype (subtype)			
1	295 (68.0)	348 (80.2)	643 (74.1)
2	14 (3.2)	6 (1.4)	20 (2.3)
3	115 (26.5)	76 (17.5)	191 (22.0)
4	0	2 (0.5)	2 (0.2)
Indeterminant	10 (2.3)	0 (0.0)	10 (1.2)
Mixed	0	2 (0.5)	2(0.2)
HCV RNA, Log ₁₀ IU/mL (median, IQR)	6.9 (6.0-11.5)	5.9 (5.5-6.2)	6.1 (5.7-7.1)
CD4 T cell count	515 (340-725)	500 (374-675)	506.5 (351-704)
Haemoglobin, g/dl (median IQR)	14.7 (13.6-15.6)	14.8 (13.5-15.9)	13.5 (15.7)
Creatinine, mg/dL (median, IQR)	71 (61-81)	70 (61-80)	70 (61-80)
ALT, U/L (median, IQR)	51.9 (37-85.6)	51.9 (37-85)	53 (36-88)
Bilirubin, mg/dL (median, IQR)	8.9 (6-13.4)	10.1 (7.2-14)	9.7 (6.6 -13.7)
Albumin, g/dL (median, IQR)	47 (44.6-49.5)	48.7 (46.6-51)	47.9 (45.5-50.3)
INR (Median IQR)	1 (0.9-1.0)	1 (1-1.03)	1 (1-1.03)

Platelets (x10 ⁹ /L) (median (IQR))	211 (170-257)	219 (186-255)	215 (179 -255)
APRI score (median IQR)	0.5 (0.3-0.9)	0.5 (0.3-0.8)	0.5 (0.3-0.8)
Fibroscan			
F0-F1	2 (0.6)	253 (71.5)	255 (36.4)
F1-F2	34 (9.8)	51 (14.4)	328 (46.8)
F3	34 (9.8)	36 (10.2)	70 (10)
F4	0 (0.0)	6 (1.7)	9 (0.9)

HCV = hepatitis C virus, PLHIV = people living with human immunodeficiency virus (HIV) infection, MSM = men who have sex with men, Partner + = sexual partner of HCV infected person, SW = sex worker, PWID = people who inject drugs, MAT= medication assisted treatment, HBV = hepatitis B virus, INR = International Normalized Ratio

Table 2: Outcomes at 24 weeks after study enrolment, by site

Outcome (n, %)	Gromashevsky	Kyiv City Hospital # 5	Total
Treatment success (SVR)	427 (98.4%)	404 (93.1%)	831 (95.73%)
Treatment failure (retained in care)	0 (0%)	29 (6.7%)	29 (3.34)
Loss to follow up after treatment initiation	6 (1.4%)	0 (0%)	6 (0.69)
Premature discontinuation	1 (0.2%)	0 (0%)	1 (0.12)
Death	0 (0%)	1 (0.2)	1 (0.12)
Total	434 (100%)	434 (100%)	868 (100%)

Following treatment initiation, 6 participants were lost to follow up (LTFU), 1 discontinued treatment prematurely and 1 died due to myocardial infarction between week 12 and week 24. Eight hundred and sixty were assessed for SVR at 24 weeks. By intention-to-treat analysis (ITT), which defined all non-successful outcomes as failures, 37 participants failed therapy, for an overall treatment success rate of 831/868 (95.7%). The SVR rates for participants with genotype 1 and 3 HCV were 95.5% and 96.3% respectively (Table 3). SVR rates differed significantly by site and by HIV coinfection status. The majority of treatment failures happened among the HIV-co-infected patients. All loss to follow up and the treatment discontinuation were from Gromashevsky clinic; the treatment failures were from Kyiv City Hospital (n=29 (Table 2). Of the 755 PWID assessed at 24 weeks, 95.2% achieved SVR.

257 **Predictors of SVR**

258 Characteristics of participants are compared between the SVR group and the non-SVR
259 group by ITT population in Table 3. There were significant differences in the odds of achieving a
260 successful treatment response by treatment site, marriage status, and HIV co-infection status in
261 both univariate and multivariate analysis.

262 **Costs**

263 Resource utilization for the first 522 participants enrolled at the Kyiv and Gromashevsky
264 study sites and locally collected unit costs are presented in Table 4, and a detailed breakdown by
265 cost component and outcome is provided in Table 5. We note that the estimates in Table 5
266 assume generic pricing for LDV/ SOF of \$1.06 per tablet; brand pricing for this medication is
267 estimated to cost \$10.61/tablet. The results shown in Table 5 are a reasonable proxy for costs
268 under “real world” conditions, with a cost per patient of \$680.

269

270 The study protocol included some resources that may not be regarded as essential for the
271 intervention, such as a Fibroscan, and that many patients actually received more laboratory tests
272 than were called for in the protocol. The cost of these excess resources is included in the estimate
273 in Table 5. If the Fibroscan were removed and the quantities of liver tests, creatinine tests, and
274 INR/PT were each cut in half, the average cost per patient would be \$616.

275

276 Table 3: Factors influencing treatment response (intention to treat, N=868)

277

Characteristic	Treatment Failure n = 37	Treatment Success (n=831)	ITT N=868	OR (95%CI) for treatment failure	p-value	AOR (95% CI) for treatment failure	p-value±
Clinics							
Gromashevsky	7(18.9)	427 (51.4)	434 (50.0)	Ref			
Kyiv City Clinic	30 (81.1)	404 (48.6)	434 (50.0)	4.5 (2.0-10.4)	0.001	6.2 (2.6-14.8)	0.001
Age (Median (IQR))	38.1 (34.4-41.7)	39.2 (35.5-44.3)		0.9 (0.09 -1.0)	1.00		
Sex (%)							
Female	8 (23.7)	287 (34.5)	295 (34)	0.5 (0.2-1.2)	0.092		
Male	29 (76.3)	544 (65.5)	573 (66)	Ref			
Education							
Primary and below	13 (34.2)	282 (34.0)	295 (34)	Ref			
Beyond Primary	24 (64.9)	549 (66.1)	573 (66)	0.9 (0.5-1.9)	0.880		
PWID (%)							
PWID	34 (94.4)	681 (86.4)	755 (87)	0.4 (0.8- 1.5)	0.110		
Non-PWID	2 (5.4)	107 (13.6)	109 (13.0)	Ref			
PWIDs (OST)	13 (100)	403 (95.)	416 (95.0)				
(%)							
PWIDS (No OST)	0 (0)	21 (5)	21 (4.8)				
(%)							
Marital Status (%)							
Never Married	24 (64.9)	675 (81.2)	699 (80.5)	ref			
Ever Married	13 (35.1)	156 (18.8)	169 (19.5)	2.3 (1.2-4.7)	0.017	2.4 (1.1-4.9)	0.023
Median BMI (Kg/m²) (IQR)	24.3 (21.5-25.5)	23.9 (21.7-26.5)	23.9 (21.6-26.5)	1.09 (0.9-0.6)	0.628		
Cirrhosis %							
Compensated	3 (8.1)	68 (8.2)	71 (8.2)	ref			
No Cirrhosis	34 (91.9)	763 (91.8)	797 (91.8)	1.0 (0.3-3.4)	0.987		
Infection Status (%)							
HCV mono-infected	6 (16.2)	377 (45.4)	383 (44.1)	ref			
HCV/HIV	31 (83.8)	448 (53.9)	479 (55.2)	4.3 (1.9-10.5)	0.001	6.9 (2.6-18.4)	0.001
HCV/HBV	0 (0.0)	3 (0.4)	3(0.3)				
HCV/HIV/HBV	0 (0.0)	3 (0.0)	3 (0.3)				

278 Adjusted OR and P value only provided for statistically significant factors

Characteristic	Treatment (Failure n=37	Treatment (Success, n=831	ITT N=868	OR (95%CI)	p-value	AOR± (95% CI)	p-value±
Genotype							
(subtype)							
1	29 (78.4)	614 (73.9)	643 (74.1)	ref			
2	1 (2.7)	19 (2.3)	20 (2.3)	1.11 (.144-8.61)	0.92		
3	7 (18.9)	184 (22.1)	191 (22.0)	0.81 (0.35-1.87)	0.61		
4	0 (0.0)	2 (0.2)	2 (0.2)				
Mixed	0 (.0)	2 (0.2)	2 (0.2)				
Indeterminant	0 (0.0)	10 (1.2)	10 (1.2)				
Haemoglobin, g/dl (Median, IQR)	14.6(13.1- 15.6)	14.7 (13.5- 15.7)	14.7 (13.5- 15.7)	0.9(0.9-1.2)	0.576		
Log10 Viral Load (Median, IQR)	5.9 (5.6-6.7)	6.2 (5.7-7.1)	6.1 (5.7-7.1)	1.1 (0.9-1.2)	0.1975		
Creatinine, mg/dL (Median, IQR)	72.5 (67-82)	70 (61 -80)	70 (61-80)	0.9 (0.9-1.0)	0.2367		
ALT U/L (Median, IQR)	53.5(30.2- 98.2)	53 (36.1-87)	53 (36 -88)	0.9 (0.9-1.0)	0.9047		
Bilirubin, mg/dl (Median, IQR)	10.1 (6.9- 17.5)	9.7 (6.6- 13.7)	9.7 (6.6 - 13.7)	0.9 (0.9-1.0)	0.0230		
Albumin, g/dl (Median, IQR)	48.2(46.3- 51.6)	47.9 (45.4 - 50.3)	47.9 (45.5- 50.3)	1.0 (0.9-1.0)	0.9498		
INR (median, IQR)	1 (0.9-1.1)	0.9 (0.9-1.0)	0.9 (0.9-1.0)	1.0 (0.4-2.8)	0.8420		
Platelets (x10 ⁹ /L)	215.5(165- 254)	215 (179- 255)	215 (179- 255)	1.0 (0.9-1.0)	0.5238		
APRI Score (Median IQR)	0.5 (0.4-0.8)	0.5 (0.3-0.8)	0.5 (0.3-0.8)	0.9 (0.7-1.4)	0.8750		
CD4 cells/μL (Median IQR)	32 (485 (367-702.5)	508 (345- 704)	506.5 (351- 704)	1.0 (0.9-1.0)	9717		

279

280

±Adjusted OR and P value only provided for statistically significant factors

Table 4. Mean resource utilization and mean HIV and HCV medication cost (USD) per participant during the 24-week study period

Resource	Mean utilized per patient	Unit cost (2018 USD)
<i>Resource quantities utilized and unit costs</i>		
Physical exam	2.0	\$4.04
Counseling visit	6.0	\$3.91
Pregnancy test	0.6	\$1.00
Fibroscan	1.0	\$45.23
HCV RNA	1.8	\$33.71
HCV genotype	1.0	\$25.31
Liver tests (ALT, AST, albumin, bilirubin)	4.1	\$5.80
CBC (Hb, Plt)	3.7	\$5.30
Creatinine	4.4	\$1.40
Urea	1.5	\$1.40
INR/PT	2.0	\$2.70
HIV screening antibody (OraQuick)	1.0	\$1.01
CD4 count	0.86	\$10.00
HIV RNA test	1.0	\$17.00
HBV testing (Surface Ab, Core Ab, Surface Ag)	1.0	\$1.86
<i>Medication costs</i>		
HIV medication (mean/HIV+ participant per 24-week study period)		\$298.96
HCV medication using generic pricing (mean per 24-week study period)		\$101.69
HCV medication as procured in the study (mean per 24-week study period)		\$912.29

HCV = hepatitis C virus, RNA = ribonucleic acid, ALT = alanine aminotransferase, AST = aspartate aminotransferase, CBC = complete blood count, Hb = hemoglobin, Plt = platelet count, INR = international normalized ratio, PT = prothrombin time, HIV = human immunodeficiency virus, HBV = hepatitis B virus, Ab = antibody, Ag = antigen

Table 5. Mean cost/patient by outcome in 2018 USD

Outcome	N (%)	Indirect costs	Events	Labs	Drugs	Mean (95% CI) cost per outcome
Success	511 (98)	174	77	171	257	679 (653-705)
Failure	7 (1)	174	65	182	206	627 (516-737)
Loss	3 (1)	141	77	145	243	606 (437-775)
Death	1 (0)	154	77	135	1,188*	1,554 (N/A)
All outcomes	522	173	77	171	258	680 (653-706)

*The patient who died was an HIV infected individual with Nevirapine (6 USD per pill) as a component of the antiretroviral regimen, incurring very high drug costs.

Discussion

In a demonstration project of an integrated, simplified protocol for treating HCV and HIV among key populations in Ukraine, of whom 87% (755) were PWIDS and 55.5% (482) were HCV/HIV co-infected, a high SVR rate of 95.7% was achieved amongst all who initiated

297 treatment. Very high retention rates were observed especially in Kyiv City clinic. Treatment
 298 success varied by site, with Gromashevsky achieving 98.4 % SVR, and Kyiv city clinic 93.1%.
 299 This is unusual success in not only a high-risk population, but also for the efficacy of SOF/LDV
 300 +/- ribavirin particularly for genotype 3 infection. A prior US trial without ribavirin reported
 301 89% SVR among genotype 3 patients without cirrhosis¹⁶, while a European study using ribavirin
 302 combination treatment reported and overall SVR of 94%¹⁷. While HIV co-infection was a risk
 303 for treatment failure, 93.6% of HIV/HCV co-infected individuals nonetheless achieved SVR. In
 304 addition only one HIV-coinfected patient was HIV viremic at 24 weeks. That may suggest the
 305 HIV/HCV co-infected who failed HCV treatment still adhered to HIV treatment.

306

307 Although PWID status was not associated with treatment failure, 91.9% (34) of those who
 308 failed were PWIDS. While adherence to HCV treatment was not measured, there was minimal
 309 loss to follow up; this may have been because of the Community Based Treatment model of
 310 care that incorporates a social worker into the clinical management team^{18,19} and also provides
 311 harm reduction services at a community level. Even among PWID, who typically have high rate
 312 of loss to follow up²⁰, there were few losses, due perhaps to the Community Based Treatment
 313 harm reduction program in Ukraine¹⁹. Other studies have demonstrated high rates of success
 314 with HCV treatment co-located with substance use treatment services and amongst PWID
 315 receiving OST^{21,22}.

316

317 Treatment with LDV/SOF and Ribavirin was generally well tolerated, with expected and
 318 manageable²³ and non-requiring treatment discontinuation.

319

320 In our study, the estimated average cost of treatment per patient initiated on HCV therapy,
 321 including the costs for both HCV and HIV treatment, was \$680. The small handful of patients

322 who did not achieve SVR or did not return for the 24-week evaluation (LTFU) cost slightly less
 323 per patient, while the single patient who died cost substantially more, due largely to expensive
 324 HIV drugs. The cost per patient treated reported here (\$680/patient) is dependent on utilizing the
 325 lowest cost testing platform to confirm HCV viremia and treatment response (the status quo
 326 Synevo labs) and securing generic pricing for HCV medications. Other laboratory platforms will
 327 likely cause the cost/patient to go up or down depending on patient volume. Reducing the
 328 frequency of laboratory tests will also reduce costs. If generic drugs cannot be obtained, the cost
 329 of treatment will be substantially higher. As HCV treatment moves towards the use of pan-
 330 genotypic drugs, further reductions in the laboratory cost component are possible with
 331 elimination of genotype testing, though the cost of the medications will likely be higher than
 332 generic LDV/SOF. For program budgeting purposes, under the assumption of generic drug
 333 pricing but higher laboratory costs, an average cost of \$750/patient is likely a reasonable
 334 estimate for this intervention. This does not include costs for scaling up or maintaining the
 335 treatment program, such as procurement, training, management, and oversight.

336

337 In conclusion, an integrated HCV/HIV treatment program in Ukraine achieved excellent
 338 outcomes with LDV/SOF+ribavirin HCV treatment in a patient population in which most
 339 individuals were co-infected with HIV and were PWID, and a substantial proportion had
 340 genotype 3 HCV infection. Loss to follow up was very low and cure rates very high. Adverse
 341 events due to RBV were minimal. The cost per patient, while relatively high for Ukraine, was
 342 modest by international standards. Going forward, a partnership among community-based
 343 organisations, private laboratories, and government that can secure generic medications and
 344 provide point of care testing may be an affordable strategy for making HCV treatment
 345 universally available in Ukraine.

346

347 **Competing interests**

348 K.W.C. has received a research grant to the institution from Merck Sharpe & Dohme. The
349 other authors who have taken part in this study declared that they do not have anything to
350 disclose regarding funding or conflict of interest with respect to this manuscript.

351 **Authors' contributions**

352 IS, SR, CC, KC, CVDH, TB, SA, conceived the study, FM, SA, YS, TB, ML, II, SM, MB
353 conducted the study, CWK, CC, analyzed the data, CC, SR, AS and CWK drafted the manuscript
354 and authors reviewed and approved the final manuscript.

355 **Funding Information**

356 USAID EQUIP Grant No. AID-OAA-A-1500070), non pharmaceutical industry funds Luxemburg
357 Business Partnership Facility 2017, Grant No. MAE/014 – 17 1620

358

359

360 **References**

- 361 1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of
362 hepatitis C virus genotypes. *Hepatology*. 2015;61(1):77-87.
- 363 2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and
364 genotype distribution of the hepatitis C virus infection. *J Hepatol*. 2014;61(1 Suppl):S45-
365 57.
- 366 3. Easterbrook PJ. Who to test and how to test for chronic hepatitis C infection - 2016 WHO
367 testing guidance for low- and middle-income countries. *J Hepatol*. 2016;65(1
368 Suppl):S46-s66.
- 369 4. Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among gay
370 and bisexual men: a systematic review. *Sex Health*. 2017;14(1):28-41.
- 371 5. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from
372 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet*.
373 2016;388(10049):1081-1088.
- 374 6. WHO. Hepatitis C. WHO. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>.
375 . Published 2016. Accessed 10/10/2020, 2020.
- 376 7. WHO. Hepatitis C in the WHO European region. . WHO.
377 [http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-](http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics/fact-sheet-hepatitis-c-in-the-who-european-region1)
378 [statistics/fact-sheet-hepatitis-c-in-the-who-european-region1](http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics/fact-sheet-hepatitis-c-in-the-who-european-region1). Published 2018. Accessed
379 10/10/2020, 2020.
- 380 8. WHO. *Global Hepatitis Report 2017*. Geneva: World Health Organization; 2017 2017.

- 381 9. Organisation WH. Global Health Sector Strategy on Viral Hepatitis 2016-2021. WHO.
382 <https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/> Published 2016.
383 Accessed 2020.
- 384 10. Organization WH. *Progress report on access to hepatitis C treatment: Focus on*
385 *overcoming barriers in low- and middle-income countries*. Geneva: WHO; 2018.
- 386 11. Health AfP. Over 5% of Ukrainians are infected with Hepatitis C. Kyiv. Alliance for
387 Public Health. [http://aph.org.ua/en/news/over-5-of-ukrainians-are-infected-with-hepatitis-](http://aph.org.ua/en/news/over-5-of-ukrainians-are-infected-with-hepatitis-c/)
388 [c/](http://aph.org.ua/en/news/over-5-of-ukrainians-are-infected-with-hepatitis-c/) Published 2016. Accessed 10/10/2020, 2020.
- 389 12. Stigma index for people living with HIV/AIDS Network for Life.
390 [http://network.org.ua/old/ru/projects/proekt-respect-zmenshennya-stigmi-ta-](http://network.org.ua/old/ru/projects/proekt-respect-zmenshennya-stigmi-ta-diskriminatsiyi-povyazanoyi-z-vil-shhodo-predstavnikov-grup-najvishhogo-riziku-v-medichnih-zakladah-ukrayini/)
391 [diskriminatsiyi-povyazanoyi-z-vil-shhodo-predstavnikov-grup-najvishhogo-riziku-v-](http://network.org.ua/old/ru/projects/proekt-respect-zmenshennya-stigmi-ta-diskriminatsiyi-povyazanoyi-z-vil-shhodo-predstavnikov-grup-najvishhogo-riziku-v-medichnih-zakladah-ukrayini/)
392 [medichnih-zakladah-ukrayini/](http://network.org.ua/old/ru/projects/proekt-respect-zmenshennya-stigmi-ta-diskriminatsiyi-povyazanoyi-z-vil-shhodo-predstavnikov-grup-najvishhogo-riziku-v-medichnih-zakladah-ukrayini/) Published 2016. Accessed 2020.
- 393 13. MOH. New Clinical Protocol of Antiretroviral Drugs for HIV infection treatment and
394 prevention [https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-](https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-05062019--1292-pro-zatverdzhennja-novogo-klinichnogo-protokolu-iz-zastosuvannja-antiretrovirusnih-preparativ-dlja-likuvannja-ta-profilaktiki-vil-infekcii)
395 [05062019--1292-pro-zatverdzhennja-novogo-klinichnogo-protokolu-iz-zastosuvannja-](https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-05062019--1292-pro-zatverdzhennja-novogo-klinichnogo-protokolu-iz-zastosuvannja-antiretrovirusnih-preparativ-dlja-likuvannja-ta-profilaktiki-vil-infekcii)
396 [antiretrovirusnih-preparativ-dlja-likuvannja-ta-profilaktiki-vil-infekcii](https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-05062019--1292-pro-zatverdzhennja-novogo-klinichnogo-protokolu-iz-zastosuvannja-antiretrovirusnih-preparativ-dlja-likuvannja-ta-profilaktiki-vil-infekcii) In. Ukraine 2019
- 397 14. Long L BA, Fox MP, Ndibongo B, Jaffray I, Sanne I Treatment outcomes and cost-
398 effectiveness of shifting management of stable ART patients to nurses in South Africa: an
399 observational cohort. . *PLoS Med* 2011;8(7).
- 400 15. Rosen S LL, Sanne I. . The outcomes and outpatient costs of different models of
401 antiretroviral treatment delivery in South Africa. . *Tropical medicine & international*
402 *health*. 2008;13(8):1005–1015.
- 403 16. Feld JJ, Ramji A, Shafran SD, et al. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-
404 Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. *Clin*
405 *Infect Dis*. 2017;65(1):13-19.
- 406 17. Moser S, Kozbial K, Laferl H, et al. Efficacy of ledipasvir/sofosbuvir plus ribavirin for
407 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
408 *Eur J Gastroenterol Hepatol*. 2018;30(3):291-295.
- 409 18. UNAIDS. Communities Deliver; THE CRITICAL ROLE OF COMMUNITIES IN
410 REACHING GLOBAL TARGETS TO END THE AIDS EPIDEMIC. UNAIDS.
411 [https://www.unaids.org/sites/default/files/media_asset/UNAIDS_JC2725_CommunitiesD-](https://www.unaids.org/sites/default/files/media_asset/UNAIDS_JC2725_CommunitiesDeliver_en.pdf)
412 [eliver_en.pdf](https://www.unaids.org/sites/default/files/media_asset/UNAIDS_JC2725_CommunitiesDeliver_en.pdf). Published 2015. Accessed 2020.
- 413 19. Health AfP. Scaling up Accessible and Effective HCV Treatment Through a Community-
414 Based Treatment Model for Most Vulnerable Populations in Resource-Constrained
415 Ukraine [http://aph.org.ua/en/our-works/ukraine/scaling-up-accessible-and-effective-hcv-](http://aph.org.ua/en/our-works/ukraine/scaling-up-accessible-and-effective-hcv-treatment-through-community-based-treatment-model-for-most-vulnerable-populations-in-the-resource-constrained-ukraine/)
416 [treatment-through-community-based-treatment-model-for-most-vulnerable-populations-](http://aph.org.ua/en/our-works/ukraine/scaling-up-accessible-and-effective-hcv-treatment-through-community-based-treatment-model-for-most-vulnerable-populations-in-the-resource-constrained-ukraine/)
417 [in-the-resource-constrained-ukraine/](http://aph.org.ua/en/our-works/ukraine/scaling-up-accessible-and-effective-hcv-treatment-through-community-based-treatment-model-for-most-vulnerable-populations-in-the-resource-constrained-ukraine/). Published 2016. Accessed 10/10/20, 2020.
- 418 20. Min Thaung Y, Chasela CS, Chew KW, et al. Treatment outcomes and costs of a
419 simplified antiviral treatment strategy for hepatitis C among mono-infected and HIV
420 and/or hepatitis B virus#x02010;co#x02010;infected patients in Myanmar. *J Viral Hepat*.
421 2020.
- 422 21. Eckhardt BJ, Scherer M, Winkelstein E, Marks K, Edlin BR. Hepatitis C Treatment
423 Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located
424 at a Syringe Service Program. *Open Forum Infect Dis*. 2018;5(4):ofy048.
- 425 22. Graf C, Mücke MM, Dultz G, et al. Efficacy of Direct-acting Antivirals for Chronic
426 Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution
427 Therapy: A Systematic Review and Meta-analysis. *Clin Infect Dis*. 2020;70(11):2355-
428 2365.

- 429 23. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose
 430 ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome.
 431 *Pharmacotherapy*. 2007;27(4):494-503.
 432
 433

Figure 2: Enrolment of participants and outcomes